This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK (TheStreet) -- Chelsea Therapeutics (CHTP) soared Thursday amid news that Danish pharmaceutical company H. Lundbeck would takeover the company for up to $658 million.
Chelsea stockholders would receive $6.44 a share in cash and contingent value rights of up to $1.50 a share.
The deal would give H. Lundbeck the rights to Chelsea's drug Northera, which the U.S. Food and Drug Administration recently approved and should release in the third quarter of 2014. The drug treats a rare form of low blood pressure linked to neurological disorders such as Parkinson's disease.